Compare HOWL & BTCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HOWL | BTCS |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.7M | 52.8M |
| IPO Year | 2021 | 2008 |
| Metric | HOWL | BTCS |
|---|---|---|
| Price | $1.08 | $1.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 393.5K | ★ 842.4K |
| Earning Date | 11-13-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.40 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,491,584.00 |
| Revenue This Year | N/A | $21.27 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 304.85 |
| 52 Week Low | $0.27 | $0.95 |
| 52 Week High | $1.27 | $3.63 |
| Indicator | HOWL | BTCS |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 36.93 |
| Support Level | $0.88 | $0.97 |
| Resistance Level | $1.12 | $1.09 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 80.00 | 19.58 |
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.